278.65
6.82 (2.51%)
| Previous Close | 271.83 |
| Volume | 404,716 |
| Price / Earnings (Forward) | 18.75 |
| Price / Sales | 2.65 |
| Price / Book | 6.73 |
| 52 Weeks Range |
| Profit Margin | 7.88% |
| Operating Margin (TTM) | 13.39% |
| Diluted EPS (TTM) | 6.89 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Quarterly Earnings Growth (YOY) | -26.70% |
| Total Debt/Equity (MRQ) | 272.12% |
| Current Ratio (MRQ) | 0.840 |
| Operating Cash Flow (TTM) | 2.62 B |
| Levered Free Cash Flow (TTM) | 2.45 B |
| Return on Assets (TTM) | 5.16% |
| Return on Equity (TTM) | 19.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | IQVIA Holdings, Inc. | Mixed | Bearish |
AIStockmoo Score
| Value 35% | -2.7 |
| AI Insight info | NA |
| Relative Valuation info | -3.8 |
| Financial Health info | -1.0 |
| Timing 35% | -0.1 |
| AI Technical info | NA |
| Technical Oscillators info | 0.5 |
| Technical Moving Averages info | -1.0 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.05 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | +37.0% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | -3.4 |
| Final Score | -1.28 |
Select this tab to load the latest available analysis.
|
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 1.05% |
| % Held by Institutions | 98.21% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |